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Summary We have investigated the efficacy of a F(ab'7)2 bispecific antibody (BsAb) with dual specificity for
the CD7 molecule in one Fab arm and for the ribosome inactivating protein (rip) saporin in the other arm, for
delivering saporin to the acute T-cell leukaemia cell line HSB-2. Saporin titration experiments revealed that
BsAb increased the toxicity of saporin 435-fold for HSB-2 cells, reducing the IC", for saporin alone from
0.1 tmol to 0.23 nmol when BsAb was included. The rate of protein synthesis inactivation brought about by
BsAb-mediated toxin delivery to HSB-2 cells was very similar to that described for conventional immunotox-
ins (IT's) with a t,o (time taken for a one log inhibition of protein synthesis compared with controls) of 46 h
obtained at a saporin concentration of I nmol and 226 h at 0.1 nmol. BsAb titration studies demonstrated a
clear dose response effect of BsAb concentration on target cell protein synthesis inhibition and cell prolifera-
tion. The absolute specificity of toxin delivery was unequivocally demonstrated by a failure of BsAb to deliver
an effective dose of saporin to the CD7- cell line HL60 and by the blocking of BsAb-mediated delivery of
saporin to HSB-2 cells with an excess of F(ab)2 fragments of the anti-CD7 antibody, HB2. These studies have
clearly demonstrated the effectiveness of this BsAb for delivering saporin to a T-ALL cell line utilising CD7 as
the target molecule on the cell surface. BsAb's would therefore appear to offer a realistic alternative to IT's for
toxin delivery to tumour cells and may even offer certain advantages over conventional IT's for clinical use.
Despite the great advances that have been made in the
treatment of both adult and childhood acute lymphoblastic
leukaemia, there are still approximately one half of all adults
and one third of all children who relapse during or following
the cessation of treatment (Chessells, 1987). The prognosis
for these patients who continue with further conventional
chemotherapy following relapse is poor (Champlin & Gale,
1989). The main current therapeutic strategy for patients with
relapsed acute leukaemia that have failed primary treatment,
is very high dose ablative chemo-radiotherapy followed by
allogeneic or autologous bone marrow transplantation
(Report from the Working Party on Leukaemia, 1988).
Allogeneic transplantation offers a considerably higher suc-
cess rate in terms of cure than autografting but HLA
matched donors are available to only a small minority in
need of a transplant (Kersey et al., 1987). The challenge
therefore is to devise alternative therapies which will prove
effective for those patients who do relapse and which might
also prove beneficial as a compliment to conventional treat-
ment, improving the overall cure rate and reducing the
toxicity of treatment overall. Targeted therapy utilising
monoclonal antibodies for selectivity delivering drugs, toxins
or radioisotopes to target tumour cells offers one possible
alternative method for the elimination of residual neoplastic
cells.
Immunotoxins (IT) are hybrid molecules comprised of a
toxin species covalently coupled, usually through a cleavable
thiol bond to an antibody (Hertler & Frankel, 1989). The
antibody confers target cell specificity on the toxin and pro-
vides the means for entry of the toxin into the cell following
internalisation of the IT by endocytotis (Press et al., 1988).
The subsequent cleavage of the toxin species from the
antibody and its route of translocation from the endosome
compartment to target ribosomes in the cytosol all act to
influence the efficacy of any particular IT. IT's have proven
highly effective at selectively killing a variety of target
tumours cells in vitro (Bregni et al., 1989; Ghetie et al., 1988;
Strong et al., 1985) and in vivo (Blythman et al., 1986;
Thorpe et al., 1985; FitzGerald et al., 1986)) and clinical
trials of IT's for a variety of malignant neoplasias are now
underway (Spitler, 1988; Laurent et al., 1988; Byers et al.,
1990). A number of major obstacles need to be overcome
before IT-type treatments make any major impact in the
clinical treatment of cancer. Problems exist regarding the
slow rate with which IT's kill target cells (Casellas et al.,
1984) and linked to this is the short half life of IT conjugates
in vivo (Scott et al., 1987), though with regard to the latter
recent improvements in coupling chemistry has led to a
prolongation of in vivo half life of IT's constructed with
Ricin A chain (Thorpe et al., 1988). Fortuitously, IT's con-
structed with saporin have an apparent longer half life in vivo
in the mouse (Blakey et al., 1988), though saporin IT's
appear to be up to 30 times more toxic than ricin A chain
IT's for liver parenchyma. Strategies need to be developed to
overcome these and similar types of problem which will be
arrived at only by careful and meticulous study ofboth the in
vitro and in vivo properties and characteristics of IT's or
BsAb's.
As an alternative to conventional IT's some workers have
constructed bispecific antibodies with dual specificities for a
tumour associated target molecule in one of the Fab arms
and for a toxin in the other (Webb et al., 1985; Glennie et
al., 1988). The major advantage here is that chemical pro-
cedures for coupling the toxin to the antibody are no longer
required and that the BsAb may be administered and allowed
to localise to the tumour cell surface prior to administration
of toxin, a strategy that may serve to reduce the immuno-
genicity and perhaps also the toxicity of the complex. We
describe here the characteristics and performance of the
BsAb HB2 x DB7-18 for delivering the ribosome inactivating
protein (rip) saporin to the T-ALL cell line HSB-2 via the
CD7 cell surface molecule. We demonstrate that this BsAb is
probably just as effective as an IT for selectively delivering a
cytotoxic dose of saporin to this T-ALL cell line.
Materials and methods
Human acute leukaemia cell lines
Three established human acute leukaemia cell lines were used
for the purposes of this study, the CD7+ T-ALL cell line
HSB-2, the CD7- promyelocytic leukaemia cell line HL60
and the CD7 weakly positive T-ALL cell line HPB-ALL. All
three cell lines were maintained in the logarithmic phase of
growth in RPMI 1640 medium supplemented with 10%
foetal calf serum (Gibco), 1 mmol glutamine, I mmol sodium
pyruvate, 100 IU ml-' benzyl penicillin and 100 lg ml-'
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streptomycin sulphate. Cells were only used when the cell
viability of the cultures exceeded 95%.
Saporin
The ribosome inactivating protein (rip) Saporin was purified
from the seeds of Saponaria officinalis as previously described
(Stirpe et al., 1983). SDS-polyacrylamide gel electrophoresis
of the final preparation revealed a single band with an M,
corresponding to 29,500 daltons. The concentration of
saporin was estimated from its absorbance at 280 nmol tak-
ing Alcm280 as equal to 0.6.
Monoclonal antibodies
The anti-saporin MoAb DB7-18 (Glennie et al., 1987) and
the anti-CD7 MoAb HB2 were used in this study. Hy-
bridoma cells secreting each of these antibodies were injected
into pristane primed mice for the production of antibody
containing ascitic fluids. The 7S IgG fractions of ascitic fluid
were isolated by precipitation with 2 M ammonium sulphate
followed by ion exchange chromatography on Trisacryl-M-
DEAE. F(ab')2 fragments for each MoAb were prepared by
limited proteolysis with pepsin at pH 4.2 as described
previously (Glennie et al., 1988).
Construction ofF(ab'y)2 bispecific antibody
A Heterodimeric F(ab'")2 bispecific antibody (BsAb) contain-
ing one Fab' arm from HB2 and the other Fab' arm from
DB7-18 (HB2 x DB7-18) was constructed as described by
Glennie et al. (1987). Briefly, F(ab')2 molecules from each
antibody were reduced to obtain Fab' fragments with hinge
region SH groups, Fab' (SH). The SH groups on one of the
Fab' (SH) species were then fully alkylated with excess
0-phenylenedimaleimide to provide free maleimide groups.
The two preparations, Fab' (mal) and Fab' (SH) were then
combined under conditions which allowed cross linking of
the maleimide and the SH groups and avoided reoxidation of
the SH groups. The final products were reduced and
alkylated to remove any minor untoward products which
may have formed by oxidation or disulphide exchange and
the final mixture fractionated according to size by
chromatography on Ultragel AcA44 (LKB-Produkter AB,
Bromma, Sweden).
Analysis ofcell surface expression ofCD7 byflow cytometry
Cells were anlaysed for surface expression of CD7 by flow
cytometry. Cells were incubated for 1 h at room temperature
with a saturating concentration of HB2 antibody. Following
the first incubation cells were washed twice and incubated
with a 1:20 dilution of fluorescein isothiocyanate conjugated
F(ab')2 fragments of a rabbit anti-mouse immunoglobulins
antisera (Sigma Chemical Co., Poole, Dorset, UK). Cell sur-
face expression of CD7 was then measured by flow cytometry.
3H-leucine incorporation by HSB-2 cells
Protein synthesis levels in HSB-2 cells exposed to BsAb and
saporin were measured by 3H-leucine incorporation into cel-
lular proteins. The method used was essentially that des-
cribed previously. Briefly triplicate cultures of HSB-2 cells at
a density of 1 x 10 cells/well in 96 well microculture plates
were exposed for 48 h at 37°C to BsAb and saporin at each
experimental concentration. Cells were then pulsed for 12 h
with 1.0 tLCi 3H-leucine (TRK 510, Amersham International,
Amersham, UK) and finally harvested onto glassfibre filters
using a Skatron cell harvester. The amount of radioactive
leucine incorporated by cells was measured by scintillation
counting the harvested cells on the glassfibre discs in a
Packard scintillation counter. Results obtained for experi-
mental cultures are expressed as a percentage of the amount
of 3H-leucine incorporation observed in untreated conrol cul-
tures.
Kinetic studies
The kinetics of protein synthesis inactivation by BsAb and
saporin was determined in 96 well microcultures of HSB-2
cells exposed to a various concentrations of saporin (range
10-11 to 10-7M) together with BsAb at 0.1 gml1'. HSB-2
cells were incubated for 2 h in supplemented leucine-free
RPMI medium at 37°C and then triplicate samples of 1 x 105
cells added to wells of a 96 well microculture plate containing
each appropriate concentration of saporin and BsAb in sup-
plemented leucine-free RPMI. Microculture plates were
maintained at 37C in a humidified atmosphere of 5% CO2 in
air and at 2, 6, 12, 24 and 48 h 1.0I&Ci 3H-leucine was added
to each well of the appropriate cultures and cells harvested
after a 1 h pulse onto glassfibre mats as described above.
Regression analysis of 3H-leucine incorporation levels (ex-
pressed as a percentage of control cultures) vs each timepoint
studied was undertaken for each saporin concentration em-
ployed. The time taken to reduce the protein synthesis level
of HSB-2 cells by one log is defined as the t1o and was
obtained from the intercept point of the regression line with
the 10% level on the regression chart.
Long term HSB-2 cultures
1 x 105 HSB-2 cells were continuously exposed to various
concentrations of saporin and BsAb in supplemented RPMI
medium in 25 cm3 tissue culture flasks maintained at 37°C in
a humidified atmosphere of 5% CO2 in air. Daily viable cell
counts were undertaken for a 1Oday period and 3H-leucine
incorporation estimated as described above in parallel 96 well
microcultures of HSB-2 cells exposed in triplicate to the same
concentrations of BsAb and saporin.
Results
Cell surface expression ofCD7 by HSB-2, HPB-ALL and
HL60 cells
Flow cytometry revealed that 98% of HSB-2 cells expressed
CD7 strongly with a mean fluorescent intensity of 259 (arbit-
rary units). Ninety five per cent of HPB-ALL cells were
effectively negative or very weakly positive for CD7 expres-
sion but a subpopulation of <5% of the cells showed
moderate expression with a mean fluorescent intensity within
this population of 63 arbitrary units. All HL60 cells were
effectively negative for CD7 expression with a mean fluores-
cent intensity of only 8.3 arbitrary units.
Specific delivery ofsaporin to the CD7+ cell line HSB-2 by
BsAb
The F(ab'7y)2 BsAb HB2 x DB7-18 with anti-CD7 specificity
in one Fab arm and anti-saporin specificity in the other arm
was constructed in order to investigate its effectiveness at
specifically delivering a lethal amount of saporin to the
CD7+ T-ALL cell line, HSB-2. The CD7- promyelocytic cell
line HL60 and the weakly positive T-ALL cell line HPB-ALL
were used as a check of target cell specificity in related
experiments. All results reported here are representative of
each experiment repeated on at least three separate
occasions.
Bispecific antibody andsaporin titration against HSB-2 cells
Triplicate cultures of 1 x 105 HSB-2 cells were exposed for
48 h to BsAb at 0.1 yg ml-' together with increasing concent-
rations of saporin (ranging from 10-12 to 1O6M). Identical
numbers of cells were exposed to concentrations of saporin
alone or saporin + an equimolar mixture ofthe two different
F(ab')2 fragments (0.05jLgm1' of each) from which the
BsAb was constructed. Cultures of untreated control cells
were set up in wells containing medium alone. 3H-leucine
incorporation ws evaluated in all cell cultures after 48 h of276 D.J. FLAVELL et al.
exposure and results expressed as a percentage of the control
levels are shown in Figure 1. An IC50 of 0.1 tLmol was
obtained for saporin alone but when the BsAb was included
the IC50 was reduced to 0.23 nmol this representing a 435-
fold increase in toxicity. F(ab'y)2 fragments together with
saporin had a negligible effect on toxicity (IC50 0.08jsmol).
In a series of similar experiments HSB-2 cells were exposed
to saporin at a concentration of 0.1 lg ml- (3.3 x 10-9 M) in
the presence of varied BsAb concentrations (range
0.001 fig ml-' to 1 itg ml-'). Representative results for
Leucine incorporation following a 48 h exposure of these cell
cultures expressed as a percentage of untreated control cells
are shown in Figure 2. A clear dose response curve was seen
with increasing concentrations of BsAb, the IC50 being
achieved at a BsAb concentration of 0.01 Ig ml-'. BsAb
alone or F(ab'y)2 fragments from the HB2 + DB7-18 MoAb's
present in equimolar concentrations over the entire concen-
tration range together with saporin at 0.1 Lg ml-' had no
significant effect on protein synthesis.
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Kinetics ofBsAb action
Experiments were conducted to determine the rate at which
various concentrations of saporin (range 10-11 to 10-7M)
inactivated protein synthesis in HSB-2 cells in the presence of
BsAb at 0.1 Lg ml-'. Figure 3 shows the regression analysis
for the rate of protein synthesis inactivation for each saporin
concentration (expressed as the log percentage control 3H-
leucine incorporation vs time). The rate of inactivation is
clearly concentration dependent and linear in nature. Regres-
sion coefficients obtained for each saporin concentration were
r = 0.908 (10-7 M), 0.912 (10-8M), 0.983 (10-9M), 0.831
(10--0 M) and 0.610 (10- " M). The time taken for a one log
inhibition of protein synthesis relative to an equivalent
number of untreated control cells is defined as the t,o and is
calculated from the intercept point of the regression line with
the 10% level on the chart, and this value, plotted against
each saporin concentration is shown in a Figure 3a graph. At
a saporin concentration 10-" M no observable inhibition of
protein synthesis was detectable and the t,o value is therefore
infinitely long and consequently unplottable on the graph. At
a saporin concentration of 10- °M the t,o was shown to be
226 h whilst at saporin concentrations of 10-9, 10-8 and
10-7M the tjo values were shown to be 46, 30 and 20 h,
respectively.
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Figure 1 Protein synthesis levels in HBS-2 cells exposed to
various concentrations of saporin alone (U U) (IC50
0.1 nmol), or in combination with 0.1 sg ml-' HB2 x DB7-18
BaAb (A *) (IC50 0.23 nmol) or F(ab')2 fragments of
HB2 + DB7-18 (O---O) (IC50 0.08pmol). Bars indicate one
standard deviation.
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Figure 2 Protein synthesis levels in HSB-2 cells exposed to
various concentrations of HB2 x DB7-18 BsAb in the absence
(O----0) and presence (U *) of 0.1 fgml-' saporin or to
HB2 + DB7-18 F(ab)2 fragments in the presence of 0.1Isg ml-'
Saporin (A A). The IC50 was achieved at a BsAb concentra-
tion of 0.011 tg ml-'. Bars indicate one standard deviation.
Figure 3 Kinetics ofprotein synthesis inactivation in HSB-2 cells
exposed to BsAb (0.1 lg ml-') together with saporin at concen-
trations ranging from 10-l" M to l0-7 M. The rate slopes shown
in b were obtained following measurement of 3H-leucine incor-
poration at 2, 6, 12, 24 and 48 h exposure of cells to BsAb in
combination with saporin at the various concentrations. a shows
the calculated t,o values (the time taken to reduce protein syn-
thesis levels by 90%) plotted against the relevant saporin concen-
tration.
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Specificity ofBsAb-mediated delivery ofsaporin to HSB-2
We undertook two different types of experiment in order to
confirm that saporin was indeed being specifically delivered
by the BsAb to HSB-2 cells via the CD7 cell surface
molecule. In the first experiment the CD7- promyelocytic cell
line HL60 and the CD7 weakly positive T-ALL cell line
HPB-ALL were exposed to concentrations of saporin (range
10-12 to 10-6M) together with BsAb (O.1 Lgml-') and 3H-
leucine incorporation evaluated after 48h as in previous
experiments. The results are shown in Figure 4 and as can be
seen the BsAb failed to deliver an effective dose of saporin to
the CD7- cell line HL60 with an identical IC", of 90 nmol
obtained for both saporin alone and for saporin in combina-
tion with BsAb. HPB-ALL, the T-ALL cell line weakly
positive for CD7 was more sensitive to saporin alone giving
an IC50 value of 51 nmol. In the presence of the BsAb the
IC" was reduced to 22 nmol, this representing a two and a
half-fold increase in toxicity compared with that obtained for
saporin alone.
In a second type of specificity experiment we attempted to
block the binding of BsAb to the CD7 target molecule on the
HSB-2 cell surface with a 10-fold excess of HB2 F(ab')2. As
in previous titration experiments HSB-2 cells were exposed to
saporin alone (ranging from l1o-2 to 10-6 M) or in combina-
tion with BsAb (0.1 iLg ml-') in the absence and presence of
a 10-fold excess of HB2 F(ab')2 (1iLgml-') and 3H-leucine
incorporation evaluated after a 48 h exposure. The results in
Figure 5 show clearly that F(ab')2 shifted the titration curve
to the right, significantly reducing the cytotoxicity of the
BsAb from an IC" of 0.22 nmol without F(ab')2 to 73 nmol
with F(ab')2 a 332-fold decrease in toxicity demonstrating
effective blocking of BsAb binding by F(ab')2.
Effects ofBsAb andsaporin on long term cultures ofHSB-2
cells
A series of experiments was undertaken to establish the
effects of various concentrations of saporin and BsAb on
HSB-2 cell proliferation and protein synthesis in cell culture
measured daily over a 1Oday period.
In the first set of experiments cultures of cells were con-
tinuously exposed to a fixed BsAb concentration of
0.1 Lgml-' in the presence of varying concentrations of
saporin ranging from 0.000001 lg ml-' (0.33 pmol) to
0.1ILgml-' (3.3 nmol) and daily cell counts and 3H-leucine
incorporations determined over a 10day period. Figure 6
shows the results obtained and demonstrates a very good
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Figure 5 Blockage of BsAb-mediated delivery of saporin to
HSB-2 cells by a 10-fold excess of F(ab'7)2 of the anti-CD7
MoAb HB2. Leucine incorporation was measured in HSB-2 cells
following a 48 h exposure to varying amounts ofsaporin together
with F(ab')2 (O *) IC50 0.18psmol, F(ab')2 + HB2 x DB7-
18 BsAb (O---O) IC5o 73 nmol, or HB2 x DB7-18 BsAb
(A *) IC5o 0.22 nmol.
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Figure 4 Protein synthesis levels in HPB-ALL and HL60 cells
following exposure to varying concentrations of saporin alone or
in combination with BsAb. HL60; saporin only IC50 90 nmol
(O---0) HL60; BsAb + Saporin IC50 90 nmol, (A -A) HPB-
ALL; saporin alone IC" 51 nmol (* *) and HPB-ALL;
BsAb + saporin (V V) lCm 22 nmol.
Figure 6 Viable cell counts a, and 3H-leucine incorporation ex-
pressed as decays per minute (d.p.m.), b, measured over a 10 day
period in cultures of HSB-2 cells exposed continuously to 0.1 ILg
ml-' HB2 x DB7-18 BsAb together with various concentrations
of saporin. No saporin (M *) or saporin at 0.000001 jig
ml-,(O O) 0.00001 1gml-l (0O O), 0.0001 1igml-I
(0 0), 0.001lugml' (03 O), 0.011tgml-' (V V)
and 0.1 lg ml- (A A).
-
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correlation between the viable cell count data (Figure 6a) and
leucine incorporation data (Figure 6b). The dose response to
saporin concentration in the presence of a fixed BsAb con-
centration of 0.1 tgml-' is clearly obvious with 0.01 gml-'
of saporin giving complete and total inhibition of both cell
division and leucine incorporation. Microscopic examination
at 10 days revealed that the vast majority of cells in these
cultures were non-viable with very rare, apparently viable
cells occasionally visible in the culture. At a saporin concen-
tration of 0.001 yg ml-' cell division was slowed to approxi-
mately two thirds that obtained with untreated control
HSB-2 cultures whilst leucine incorporation was reduced to
less than half that seen in the control cultures. Saporin
concentrations of 0.0001 jg m'l (3.3 pmol) or less had little
or no effect.
In similar experiments we continuously exposed cultures of
HSB-2 cells to saporin at two fixed concentrations of
0.1 tg ml-' (3.3 nmol) (Figures 7a and b) or 0.01 gml-'
(0.33 nmol) (Figures 7c and d) in the presence of various
concentrations of BsAb ranging from 0.001 Lgml-' to
0.1 jgml-'. Viable cell counts and 3H-leucine incorporation
was determined for each culture daily over the 10 day period
of the experiment and the results presented as a percentage of
control cultures. The dose response to BsAb concentration
over the time course of the experiment is clearly obvious in
cultures treated with 0.1 lg ml-' saporin (Figures 7a and b),
there being an extremely good correlation between viable cell
count and leucine incorporation over the range of BsAb
concentrations used. Thus, BsAb used at 0.01 and
0.1 tgml-' was effective at totally inhibiting HSB-2 cell
division and protein synthesis at a saporin concentration of
0.1 agml-1 whilst cells treated with 0.005ggml-' BsAb
showed a shallower reduction and cell proliferation and pro-
tein synthesis began to increase once again by day 9 (Figures
7a and b). At a BsAb concentration of 0.001 fgml-' viable
cell count and protein synthesis levels dropped to a nadir by
day 5 but began to recover thereafter achieving control levels
by day 8.
At a saporin concentration of0.01 jgm'l (Figures 7c and
d) the only effective BsAb concentration which completely
inhibited cell proliferation and protein synthesis in the cul-
tures was 0.1 tgml-'. BsAb concentrations of 0.005ggml-'
and 0.01 gml-' both caused a transient depression in both
viable cell count (Figure 7c) and protein synthesis levels
(Figure 7d) which reached their nadir by day 5 showing
approximately half the values seen in control cultures. How-
ever, by day 7 to 8 both viable cell count and protein
synthesis levels began to increase reaching control levels by
the end of the experiment.
saporin treatment with an observed ICso of 0.38 nmol, this
representing a 579-fold increase in toxicity above that seen
with saporin alone (ICs 0.22ytmol) in this particular experi-
ment (data not shown).
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Multiple treatment studies
In order to establish whether surviving HSB-2 cells
previously treated with saporin and BsAb were more resist-
ant to subsequent rounds of treatment we conducted the
following experiments. HSB-2 cells surviving continuous
exposure to 0.1figml-' saporin + 0.01 ggml-' BsAb from
the experiment shown in Figures 7a and b began to divide
after 10 days in culture. By day 17 there were sufficient cells
(5 x 105) to repeat a further round of treatment with the
same levels of BsAb and saporin. Once HSB-2 cells surviving
this second round of treatment, began dividing again, they
were washed, put into fresh complete RPMI medium and
grown to high density prior to investigation. These twice
treated HSB-2 cells were designated HSB-2(G +). Prior to
study HSB-2(G +) and untreated HSB-2 cells were analysed
by flow cytometry for cell surface CD7 expression using the
native anti-CD7 MoAb HB2. There were no observed
differences in the level of cell surface expresson of CD7
between the native HSB-2 cells and HSB-2(G +) cells (data
not shown).
HSB-2(G +) cells were exposed for 48 h to increasing con-
centrations of saporin (range 10-12 to 10-6 M) together with
BsAb (0.1 gml-') and 3H-leucine incorporation evaluated.
HSB-2(G +) cells were still found to be sensitive to BsAb/
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Figure 7 Viable cell counts a, and c and 3H-leucine incorpora-
tion expressed as a percentage of control b, and d, measured over
a 10 day period in HSB-2 cell cultures exposed to either 0.1 fig
ml-' saporin a and b, or 0.01 jg ml-' saporin c and d, together
with various concentrations of HB2 x DB7-18 BsAb BsAb at
0.001 ptgml' (O 0), 0.005fsgml-' (* *), 0.01 tg
ml-' (A A) and 0.1 gml- (A A). Cultures were also
exposed to saporin alone (O *) and BsAb alone (0 0).BISPECIFIC ANTIBODY DELIVERY OF SAPORIN 279
Discussion
The present study has clearly shown that a F(ab'y)2 bispecific
antibody (BsAb) with dual anti-CD7 and anti-saporin
specificities can effectively and specifically deliver a cytotoxic
dose of saporin to the CD7+ T-ALL cell line HSB-2. The
cytotoxic response following BsAb-mediated delivery of
saporin to HSB-2 cells was dose dependent in terms of both
BsAb and saporin concentrations. We were also able to
demonstrate a very good correlation between BsAb/saporin-
mediated inhibition of cell proliferation and inhibition of
protein synthesis in 10 day cell cultures and moreover
observe that cell death was actually occurring in these cul-
tures.
CD7 has been successfully used as the target molecule on a
variety of fresh and established human leukaemia cell lines
for targeting intact ricin (Strong et al., 1985), ricin A chain
(Myers et al., 1984) and single chain ribosome inactivating
proteins (rip) (Ramakrishnan & Houston, 1984). An
immunotoxin constructed with the anti-CD7 MoAb 3A1 and
the rip pokeweed antiviral protein (PAP) was highly
cytotoxic for the T-ALL cell line HSB-2 with an observed
IC50 of 0.11 nmol (Ramakrishnan & Houston, 1984). This
IC50 value is very close to that obtained for BsAb-mediated
delivery of saporin via the CD7 molecule also on HSB-2 cells
(IC500.23 nmol) observed in the present study and suggests
that BsAb can deliver toxin with a similar efficiency as IT.
This is an interesting observation as BsAb delivers rip to the
cell surface univalently without cross linking adjacent CD7
molecules on the cell surface. This is in contrast to IT's
constructed with intact immunoglobulin molecules which are
bivalent and therefore do cross link adjacent target molecules
on the cell surface. Thus, one might expect IT's to deliver the
toxin/rip more effectively by virtue of increased binding
affinity at the cell surface through two target molecules and
perhaps more importantly due to the increased rate of
modulation and subsequent internalisation that occurs when
adjacent target molecules are cross linked at the cell surface.
Unfortunately, there are to the best of our knowledge no
published reports of anti-CD7 IT's constructed with saporin
and therefore valid statements about BsAb vs IT-mediated
delivery of saporin cannot really be made until these have
been compared directly on the same cell line. We are plann-
ing experiments to address this issue in the near future.
Saporin is a single chain ribosome inactivating protein
(Stirpe et al., 1983) and unlike intact ricin does not have any
intrinsic means of entering the cell and therefore becomes
cytotoxic only at relatively high concentrations (in the pre-
sent study the ICo of saporin for HSB-2 cells was 0.1 .Imol).
The toxicity that is seen at relatively high concentrations of
saporin is probably due to the entry of small amounts of
saporin into the cell by fluid pinocytosis. BsAb reduced the
ICm for HSB-2 to 0.23 nmol, a 435-fold increase in toxicity
over saporin alone. The specificity of saporin delivery by
BsAb was unequivocally demonstrated by two different
methods. In the first BsAb + saporin was shown to have no
cytotoxic effect on the CD7- cell line HL60 and had only a
small effect on the weak CD7+ positive cell line HPB-ALL.
The two and a half-fold decrease in IC5o that BsAb gave for
HPB-ALL almost certainly represents the delivery of only a
small amount of saporin to the target ribosomes in the cell
interior due to the very low or non-existant density of target
antigen expression by the majority of HPB-ALL cells. As one
might expect, this clearly demonstrates the importance of the
level of cell surface target antigen expression that has been
commented on previously by other workers (Laurent et al.,
1986).
The observation that HSB-2(G +) cells that had been put
through two cycles of BsAb and saporin treatment were
equally as sensitive as previously untreated HSB-2 cells, to
subsequent rounds of BsAb/saporin treatment provides an
important clue as to how these cells escaped destruction in
the first instance. There were no observed differences between
HSB-2(G +) and HSB-2 cells for cell surface expression of
CD7 showing that a subpopulation of variant target antigen
negative cells had not been selected for by BsAb/saporin
treatment. This is unlike the findings of Glennie et al. (1988)
where target guinea pig L2C tumour cells emerging following
BsAb/saporin treatment in vivo were target antigen negative.
Similarly, a transferrin-Ricin A chain resistant clone of the
T-cell line CEM had reduced levels of expression of the
target transferrin receptor molecule (CD71) (Raso & Basala,
1984) though it has not always been possible to correlate
sensitivity to an immunotoxin and the level of expression of
the target antigen by the target cell (Goldmacher et al.,
1987). The retained sensitivity of HSB-2(G +) cells to BsAb/
saporin also excludes the possibility that we had selected for
a subpopulation of HSB-2 cells with an inherent defect in
endocytosis transport of BsAb-saporin complexes across the
membrane (Goldmacher et al., 1987), or with endosome-
cytosol translocation of toxin to the target ribosome. We feel
that the most likely explanation is quite simply that a small
proportion of the original HSB-2 cells at the time of BsAb/
saporin treatment were negative or weakly positive for CD7
expression and therefore escaped lethal intoxication at this
time. Following their subsequent outgrowth some weeks
later, by which time the majority of the BsAb/saporin had
been consumed or had degraded in culture, these cells then
upregulated their CD7 expression and were therefore acces-
sible to saporin delivery with the BsAb when so treated on a
future occasion. This likely possibility really underlines the
potential shortcomings of toxin delivery via a single target
molecule and argues strongly for using multiple target
molecules for toxin delivery, firstly to overcome the
heterogeneity of target molecule expression within a tumour
cell population and secondly to deliver greater amounts of
toxin to those tumour cells that are positive for all target
molecules.
IT's have been used for the ex vivo purging of residual
leukaemic blasts from bone marrow harvested from acute
leukaemia patients in remission prior to autografting (Strong
et al., 1985). Autografting is a significantly less toxic pro-
cedure than allografting but is also less successful with the
majority of patients relapsing post-transplant (Kersey et al.,
1987). Indications are that the graft vs host disease that often
accompanies allogeneic transplantation provides an effective
anti-leukaemia response (graft vs leukaemia) that serves to
eliminate residual leukaemic blasts within the patient (But-
turini et al., 1987). It is this particular effect, absent in
autologous transplantation, that might be partially, if not
wholly responsible for the lower success rate of autografting.
In view of the high toxicity of the allografting procedure and
the limited availability of matched donors, methods for im-
proving the success rate in autografting would represent a
major step forward in the treatment of relapsed disease. It is
not clear whether the relapses that occur following autograft-
ing do so from residual leukaemic stem cells remaining in the
patient or in the reinfused marrow inoculum. In practice
both may contribute and future objectives should aim to
reduce residual tumour cell numbers to the absolute
minimum achievable. Thus, in vivo administration of IT's
during conditioning prior to transplant, for the elimination of
residual disease in the patient combined with ex vivo treat-
ment of the patients own harvested marrow prior to rein-
fusion may lead to some improvement. There is thus a strong
case for developing IT type therapies for in vivo use and
recently small clinical studies have been undertaken in
leukaemia (Laurent et al., 1988; Byers et al., 1990) and other
malignant tumour types (Spitler, 1988).
The clinical utility of BsAb's for targeting toxins to
unwanted neoplastic cells in vivo yet remains to be seriously
explored. Glennie et al. (1988) have undertaken in vivo
immunotherapy studies in guinea pigs bearing the guinea pig
B-lineage acute lymphoblastic leukaemia tumour L2C,
targeting saporin against an idiotypic determinant on the
tumour cell surface with a BsAb. In these studies there was a
significant prolongation of survival in animals receiving
saporin and BsAb, the extent ofwhich was determined by the
route of administration and molar ratio of BsAb to saporin
employed. It is essential that the behaviour and performance280 D.J. FLAVELL et al.
of BsAb's for delivering toxins to human leukaemia cells is
thoroughly investigated in vivo in an animal xenograft model
prior to any attempt to utilise them clinically. To this end we
are actively developing a model of human acute leukaemia in
severe combined immunodeficient (scid) mice (Kamel-Reid et
al., 1989) with the objective of commencing immunotherapy
trials with BsAb's in these animals in the very near future.
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